Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib Research Letter

   

Authors:	Brown, J. R.; Zelenetz, A.; Furman, R.; Lamanna, N.; Mato, A.; Montillo, M.; O’Brien, S.; Dubowy, R.; Gu, L.; Munugalavadla, V.; Robak, T.; Hillmen, P.
Title:	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib
Journal Title:	Leukemia
Volume:	34
Issue:	12
ISSN:	0887-6924
Publisher:	Nature Publishing Group
Date Published:	2020-12-01
Start Page:	3404
End Page:	3407
Language:	English
DOI:	10.1038/s41375-020-0974-y
PUBMED:	32655145
PROVIDER:	scopus
PMCID:	PMC7829041
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087807912&doi=10.1038%2fs41375-020-0974-y&partnerID=40&md5=f482014cf7ea8d6e0d5ec773d06e3ace
Notes:	Article -- Export Date: 1 December 2020 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/173353